In the months after 24-year-old D.J. was diagnosed with schizophrenia, he searched online for answers to questions that felt urgent and existential.

This review examined whether switching to a different antipsychotic medicine, as opposed to continuing treatment with the same one, improved people's response rates, alleviated overall and specific ...

An estimated 26% of youth take at least one psychotropic drug while in the foster system, according to Children’s Rights, a ...

Members of a national coalition are urging HHS and CMS to revisit what they’ve deemed a flawed measure in CMS’ Five-Star ...

Foster youth are frequently put on psych meds, an Imprint investigation reveals. State agencies are dropping the ball on ...

The rise of psychiatric meds in children raises questions about the long-term impact, skill development, and societal standards. Are we treating illness or enforcing conformity?

Cobenfy was approved by the Food and Drug Administration in fall 2024 and represents the first novel approach in decades to ...

The purpose of black box warnings is to draw immediate attention to the most serious potential adverse effects of a drug, ...

D.J. became one of the first in line to try the new antipsychotic, called Cobenfy — a potentially life-changing drug for one of psychiatry’s most intractable mental illnesses, but whose long-term side ...

Health New Zealand has acknowledged “significant failings” and apologised for the “traumatic experience” of an 11-year-old ...

New guidelines have been developed for the treatment of schizophrenia through a collaborative effort of international experts ...

What role could vitamin E play in the treatment of tardive dyskinesia, and what should patients know about managing their ...